Neuromodulation techniques have been successfully used for a variety of neuropathic pain conditions. Th e aim of this paper is to present a case of the successful use of a subcutaneously placed peripheral nerve stimulator for treatment of intractable postherpetic neuralgia (PHN). A 57-year old man presented with a two-year history of left thoracic pain that developed aft er a vesicular rash. Focal neuropathic pain had not responded to treatment with multiple analgesic medications and steroid injections. Th e patient had signifi cant relief following implantation of a peripheral nerve stimulator. Th is case represents a contribution to the small but growing body of evidence indicating that peripheral nerve stimulation may be an eff ective option for treatment of PHN not responsive to less invasive modalities.
Introduction
Postherpetic neuralgia is defi ned as pain persisting or recurring at the site of a herpes zoster rash. Th e annual incidence has been reported as 11 per 100,000 with a lifetime prevalence of 70 per 100,000 (1) . Th e pain associated with PHN is notoriously diffi cult to treat (2) .
Neuromodulation techniques have been successfully used to treat a variety of neuropathic pain conditions. Electrodes placed in the epidural space have been used to treat thoracic postherpetic neuralgia (3) . Subcutaneously placed peripheral nerve stimulation leads have been used to successfully treat a wide range of conditions, including postherpetic trigeminal neuralgia (4) . Published cases detailing the use of peripheral nerve stimulation(PNS) in the treatment of postherpetic radicular pain have been sparse (5, 6) . We present a case of the successful use of PNS in the treatment of PHN.
Neuromodulation is a reversible blockade or manipulation of pain pathways to modify physiological function and may be applied to the deep brain structures, motor cortex, spinal cord or peripheral nerves (7) . Th e mechanism of pain relief with peripheral nerve stimulation is not clearly understood. One theory is based on the gate control theory of pain, as outlined by Melzac and Wall (8) . By this theory, transmission of pain signals to the central nervous system is determined by the balance between large and small fi ber activity in the dorsal horn and spinal cord, with small fi ber input tending to maintain an open gate to pain transmission and large fiber input tending to close the gate.
Since electrical stimulation depolarizes large fi bers before it aff ects small fi bers, the theory suggests that it should be possible for stimulation to halt the transmission of pain signals. Th is explanation for the function of PNS in pain control is somewhat controversial. An alternative theory is that repetitive stimulation of peripheral nerves may produce excitation failure in c-fi ber nociceptors and suppress activity in the dorsal horn of the spinal cord. Stimulation induced blockade of cell membrane depolarization may prevent axonal conduction (9) . PNS may also function to decrease the release of excitatory neurotransmitters and increase the release of inhibitory neurotransmitters at the dorsal horn (10) .
Spinal cord stimulation has been performed for the treatment of neuropathic pain complaints for 35 years. Th ough the fi rst studies on implantable PNS therapies were produced in the 1960's, in recent years spinal cord stimulation (SCS) has been the more accepted modality for neuropathic pain (11) . Early published reports of PNS showed that a minority of patients had signifi cant pain relief.
Currently most implantable pulse generators are designated as SCS generators and are used for peripheral nerve stimulation on an "off -label" basis. Improvements in electrode and generator technology, as well as the development of percutaneous implantation techniques, have led to a resurgence of interest in the PNS modality.
Recent years have seen PNS used successfully for conditions ranging from postoperative or posttraumatic neuropathies (12) to migraine (13) , low back pain (14) and fi bromyalgia (15) . As part of a larger study of the use of PNS for patients with facial pain, Johnson, et al. (4) 
Case report
A 57-year old man with a history of multiple myeloma and chronic renal insuffi ciency presented with a two year history of PHN aft er developing a vesicular rash in the left fi ft h thoracic dermatome. At the time of initial evaluation, the patient described a burning, lancinating, electrical type of pain that he rated as 9 out of 10 on the visual analogue scale (VAS). Th e pain was primarily focused in the left periscapular region. Th e patient reported a history of increased pain when air, clothing, or the shower would touch his skin. Sensory examination revealed allodynia just inferior to the left scapula. No scarring of the skin was evident. Motor function was normal. MRI of the thoracic spine showed no pathology in the region of the pain. He was treated with two series of intercostal nerve blocks, as well as an interlaminar thoracic epidural steroid injection, without relief. He had also been treated with multiple analgesic medications. A lidocaine patch was ineff ective, as was a topical compounded cream of amitriptyline, gabapentin, and lidocaine. Gabapentin, pregabalin, and baclofen were tried in succession and were not tolerated due to sedation. Nortriptyline was ineff ective. Th e use of a transcutaneous electric nerve stimulation (TENS) unit only exacerbated his pain. Th e patient was escalating use of oxycodone and at the time of the electrical stimulation trial was taking 60 to 80 mg daily.
Th e patient agreed to undergo trial treatment with electrical stimulation therapy. During such a trial, an electrode is placed percutaneously and attached to an external pulse generator. Th e trial implantation is performed under minimal conscious sedation in order to determine the location of the paresthesia produced and to determine the patient's response to simulation. Th e patient is then typically discharged with the epidural lead in place with a follow-up visit scheduled several days later. At the time of follow up, the patient's response to stimulation is recorded and the percutaneous lead is removed. Signifi cant pain relief during such a trial indicates that the patient will likely have a good outcome from permanent stimulator implantation. In this case, the trial was carried out with placement of both epidural and subcutaneous leads.
Aft er carefully outlining the area of pain and obtaining informed consent, the patient was taken to the surgical suite. He was placed in a prone position and the lower and mid back was prepped and draped in a sterile fashion. Th e patient was under light conscious sedation and was monitored throughout the case. Aft er anesthetizing the skin, a 14 gauge Tuohy needle was placed into the epidural space under fl uoroscopic guidance at the T12-L1 level using loss of resistance technique. An eight contact electrode (Octrode TM ) lead (St Jude Medical, Plano, TX) was placed through the Tuohy needle, into the epidural space, with the most superior lead at the midportion of the T1 vertebral body, 0.5 mm to the left of midline. Th e lead was attached to a St. Jude pulse generator and paresthesia was produced covering the area of left thoracic pain. A second identical lead was placed percutaneously through a 14 gauge Tuohy needle into the subcutaneous space in the area of the left T5 dermatome. Th e electrode was placed medial to and slightly superior to the location of his most signifi cant pain and allodynia. Th is electrode was attached to the pulse generator and was tested with the epidural lead inactivated. Th e subcutaneous lead also produced paresthesia in the distribution of his pain. Tuohy needles and styletes were removed from each site and the percutaneous leads were sutured to the skin. Th e patient was seen in the recovery room for further fi ne tuning of programming. Th e epidural and subcutaneous lead both proved to be equally eff ective, producing paresthesia and relief of the patient's thoracic pain. Th e patient was discharged for a 72 hour trial period. He was provided with programs to activate both electrodes individually or both simultaneously. During the trial period, the patient reported 75% reduction in pain and his opioid requirements only amounted to 25% of his typical daily use. Th e patient reported equivalent pain relief regardless of which electrode was activated. At the time of follow up, both percutaneous leads were removed.
Six weeks aft er the trial period, the patient returned for permanent implantation. He had a history of coagulopathy, likely due to his history of multiple myeloma and treatment with chemotherapeutic agents. Due to bleeding during the procedure, the decision was made to proceed with implantation of subcutaneous leads, rather than to perform a laminectomy for epidural placement. Th e implantation was performed under general anesthesia with assistance from a neurosurgeon. Th e initial percutaneous lead was placed in a location identical to the subcutaneous trial lead. In order to provide additional coverage of any more lateral symptoms, a second subcutaneous lead was placed approximately 3 inches lateral to the fi rst lead, in the path of the T5 dermatome. A subcutaneous pocket was produced in the upper left buttock and a St Jude Eon Mini rechargeable implantable pulse generator was implanted.
At 6 months follow-up, the patient reported decreased pain and improved quality of life. Th e maximum pain level had diminished from 10/10 to 4/10 on VAS. Th e constant burning pain had been completely alleviated but he continued to report occasional lancinating pain. At the time of the last follow-up, he had decreased his use of oxycodone 5 to 10 mg a day.
Discussion
We report a case of the successful use of a subcutaneously placed peripheral nerve stimulator for the treatment of postherpetic neuralgia. Th is adds to a very small but growing body of literature indicating that peripheral nerve stimulation may be a useful option in the treatment of this relatively common and potentially disabling condition. Th is study is, of course, limited in that it is a single case report. Prospective studies are needed to establish the utility and safety of PNS for the management of postherpetic neuralgia. Th e use of PNS entails the risk of nerve injury, bleeding or infection, as well as lead migration or fracture (17) . PNS treatment carries a signifi cant up front cost. A cost benefi t analysis of SCS and PNS for treatment of chronic pain showed that cost benefi ts began to accrue aft er two years of stimulator use (18) . Th ere is insuffi cient data to make a similar claim for the use of PNS alone for chronic pain or for either modality for this particular indication. One clinical limitation of our case was the placement of an additional subcutaneous lead during the permanent implantation. Th e decision to place this additional lead was made during the surgical procedure when bleeding led to aborting the placement of the epidural lead. Placement of a stimulator lead without trial on a conscious patient may entail additional procedural cost with uncertain clinical efficacy. At this stage in the use of PNS for the treatment of neuropathic pain, guidelines for the correct position or number of subcutaneous leads required or the proper duration of the trial period have not been clearly established.
Conclusion
PNS may be an eff ective treatment option for patients who have not responded to more conservative treatment. Prospective studies may be useful to determine the long term effi cacy of this technology in the treatment of post-herpetic neuralgia, as well as to determine cost eff ectiveness.
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